Dupilumab Use in Patients With Hypereosinophilic Syndromes: A Multicenter Case Series and Review of the Literature.

ABSTRACT:

Background

Hypereosinophilic syndromes (HES) are defined as hypereosinophilia with eosinophil-related clinical manifestations, some of which overlap in presentation with asthma, atopic dermatitis, eosinophilic esophagitis, and/or chronic rhinosinusitis with nasal polyps. Dupilumab is approved to treat these conditions but can induce a transient rise in the absolute eosinophil count and rare eosinophil-related complications.

Objective

To determine whether eosinophil-related complications of dupilumab are increased in HES.

Methods

Retrospective chart review of patients with HES treated with dupilumab enrolled on an institutional review board-approved research protocol at the National Institutes of Health (NCT00001406) or receiving care at Walter Reed National Military M

SUBMITTER: Ezekwe EAD 

PROVIDER: S-EPMC11717594 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature